Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$22.39 - $38.94 $261,604 - $454,974
-11,684 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$30.13 - $50.0 $352,038 - $584,200
11,684 New
11,684 $441,000

Others Institutions Holding RXDX

About Prometheus Biosciences, Inc.


  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Arrowstreet Capital, Limited Partnership Portfolio

Follow Arrowstreet Capital, Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.